United States Pharmaceuticals

XenoPort Inc (XNPT)

Track

Ticker: XNPT Exchange: NSQ
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
No insider activity signals detected

Insider trades have not triggered unusual activity signals for this company.

Top insiders
Trades
Flynn James E
2 purchases — total 83,647 USD
Buy 19 Feb 2016
Value US$4,769,147.74 | Price 416.56 | Shares 21,150
Buy 19 Feb 2016
Value US$3,116,487.73 | Price 377.94 | Shares 27,761
Buy 12 Feb 2016
Value US$4,354,689.90 | Price 295.99 | Shares 30,609
Buy 12 Feb 2016
Value US$4,902,842.38 | Price 223.85 | Shares 4,924
Buy 11 Feb 2016
Value US$4,349,642.01 | Price 3.76 | Shares 1,157,189
Buy 11 Feb 2016
Value US$3,417,579.89 | Price 3.76 | Shares 909,221
Buy 11 Feb 2016
Value US$6,166,839.98 | Price 3.96 | Shares 1,557,991
Buy 11 Feb 2016
Value US$4,845,375.12 | Price 3.96 | Shares 1,224,136
Buy 20 Jan 2016
Value US$1,418,404.41 | Price 4.09 | Shares 346,417
Sale 11 Nov 2015
Value US$6,074.12 | Price 6.68 | Shares 909
Planned sale 15 Jul 2015
Value US$90,000.00 | Price 7.20 | Shares 12,500
Buy 11 May 2015
Value US$28,169.00 | Price 5.63 | Shares 5,000
Sale 10 Dec 2014
Value US$21,225.00 | Price 8.49 | Shares 2,500
Sale 10 Dec 2014
Value US$47,476.08 | Price 8.49 | Shares 5,592
Sale 10 Dec 2014
Value US$24,773.82 | Price 8.49 | Shares 2,918
Sale 8 Dec 2014
Value US$25,200.00 | Price 8.40 | Shares 3,000
Sale 8 Dec 2014
Value US$16,700.00 | Price 8.35 | Shares 2,000
Sale 8 Dec 2014
Value US$8,444.80 | Price 8.32 | Shares 1,015
Sale 8 Dec 2014
Value US$8,302.60 | Price 8.30 | Shares 1,000
Sale 8 Dec 2014
Value US$80,001.35 | Price 8.35 | Shares 9,581
Sale 8 Dec 2014
Value US$38,284.75 | Price 8.35 | Shares 4,585
Sale 5 Dec 2014
Value US$168,000.00 | Price 8.40 | Shares 20,000
Sale 5 Dec 2014
Value US$180,418.35 | Price 8.45 | Shares 21,348
Sale 4 Dec 2014
Value US$62,896.68 | Price 8.50 | Shares 7,399
Sale 4 Dec 2014
Value US$95,658.38 | Price 8.50 | Shares 11,253
Sale 9 Sep 2014
Value US$29,519.12 | Price 5.26 | Shares 5,612
Buy 3 Jun 2014
Value US$49,163.75 | Price 3.93 | Shares 12,500
Buy 27 May 2014
Value US$10,179.26 | Price 3.92 | Shares 2,600
Buy 27 May 2014
Value US$39,900.00 | Price 3.99 | Shares 10,000
Buy 27 May 2014
Value US$12,045.90 | Price 4.02 | Shares 3,000
Buy 23 May 2014
Value US$9,744.80 | Price 3.75 | Shares 2,600
Buy 23 May 2014
Value US$35,354.25 | Price 3.72 | Shares 9,500
Buy 23 May 2014
Value US$111,978.00 | Price 3.73 | Shares 30,000
Buy 22 May 2014
Value US$20,622.80 | Price 3.75 | Shares 5,500
Planned sale 15 May 2014
Value US$9,150.00 | Price 3.66 | Shares 2,500
Sale 14 Jun 2013
Value US$40,125.00 | Price 5.35 | Shares 7,500
Buy 22 May 2013
Value US$109,800.00 | Price 5.49 | Shares 20,000
Buy 9 Aug 2012
Value US$84,983.00 | Price 8.50 | Shares 10,000
Buy 16 Dec 2011
Value US$38,580.00 | Price 3.86 | Shares 10,000
Buy 21 Nov 2011
Value US$44,413.00 | Price 4.44 | Shares 10,000
Buy 7 Nov 2011
Value US$27,451.50 | Price 5.49 | Shares 5,000
Buy 12 Nov 2010
Value US$2,358.00 | Price 7.86 | Shares 300
Buy 12 Nov 2010
Value US$275.45 | Price 7.87 | Shares 35
Buy 12 Nov 2010
Value US$792.00 | Price 7.92 | Shares 100
Buy 12 Nov 2010
Value US$793.00 | Price 7.93 | Shares 100
Buy 12 Nov 2010
Value US$6,071.04 | Price 7.94 | Shares 765
Planned sale 1 Feb 2010
Value US$1,847.00 | Price 18.47 | Shares 100
Planned sale 1 Feb 2010
Value US$1,843.00 | Price 18.43 | Shares 100
Planned sale 1 Feb 2010
Value US$1,858.00 | Price 18.58 | Shares 100
Planned sale 1 Feb 2010
Value US$1,861.00 | Price 18.61 | Shares 100
Planned sale 1 Feb 2010
Value US$1,852.00 | Price 18.52 | Shares 100
Planned sale 1 Feb 2010
Value US$1,850.00 | Price 18.50 | Shares 100
Planned sale 1 Feb 2010
Value US$1,846.00 | Price 18.46 | Shares 100
Planned sale 1 Feb 2010
Value US$1,839.00 | Price 18.39 | Shares 100
Planned sale 1 Feb 2010
Value US$1,832.00 | Price 18.32 | Shares 100
Planned sale 1 Feb 2010
Value US$1,830.00 | Price 18.30 | Shares 100
Planned sale 1 Feb 2010
Value US$3,672.00 | Price 18.36 | Shares 200
Planned sale 1 Feb 2010
Value US$3,698.00 | Price 18.49 | Shares 200
Planned sale 1 Feb 2010
Value US$1,857.00 | Price 18.57 | Shares 100
Planned sale 1 Feb 2010
Value US$3,720.00 | Price 18.60 | Shares 200
Planned sale 1 Feb 2010
Value US$563.70 | Price 18.79 | Shares 30
Planned sale 1 Feb 2010
Value US$37.60 | Price 18.80 | Shares 2
Planned sale 1 Feb 2010
Value US$1,279.08 | Price 18.81 | Shares 68
Planned sale 1 Feb 2010
Value US$1,868.00 | Price 18.68 | Shares 100
Planned sale 1 Feb 2010
Value US$1,872.00 | Price 18.72 | Shares 100
Planned sale 4 Jan 2010
Value US$1,920.00 | Price 19.20 | Shares 100
Planned sale 4 Jan 2010
Value US$1,917.00 | Price 19.17 | Shares 100
Planned sale 4 Jan 2010
Value US$1,952.00 | Price 19.52 | Shares 100
Planned sale 4 Jan 2010
Value US$1,936.00 | Price 19.36 | Shares 100
Planned sale 4 Jan 2010
Value US$616.32 | Price 19.26 | Shares 32
Planned sale 4 Jan 2010
Value US$5,159.00 | Price 19.25 | Shares 268
Planned sale 4 Jan 2010
Value US$3,856.00 | Price 19.28 | Shares 200
Planned sale 4 Jan 2010
Value US$1,923.00 | Price 19.23 | Shares 100
Planned sale 4 Jan 2010
Value US$3,844.00 | Price 19.22 | Shares 200
Planned sale 4 Jan 2010
Value US$1,927.00 | Price 19.27 | Shares 100
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2016-02-23 2016-02-19 B Purchase Flynn James E Large shareholder
21,150 +17.2%
416.56
US$4,769,148 		21,150 +17.2% 416.56 US$4,769,148
2016-02-23 2016-02-19 B Purchase Flynn James E Large shareholder
27,761 -46.8%
377.94
US$3,116,488 		27,761 -46.8% 377.94 US$3,116,488
2016-02-16 2016-02-12 B Purchase Flynn James E Large shareholder
30,609 +45.5%
295.99
US$4,354,690 		30,609 +45.5% 295.99 US$4,354,690
2016-02-16 2016-02-12 B Purchase Flynn James E Large shareholder
15,499 +0.7%
3.92
US$60,803 		15,499 +0.7% 3.92 US$60,803
2016-02-16 2016-02-11 B Purchase Flynn James E Large shareholder
1,157,189 +74.3%
3.76
US$4,349,642 		1,157,189 +74.3% 3.76 US$4,349,642
2016-02-16 2016-02-11 B Purchase Flynn James E Large shareholder
909,221 +74.3%
3.76
US$3,417,580 		909,221 +74.3% 3.76 US$3,417,580
2016-02-16 2016-02-11 B Purchase Flynn James E Large shareholder
1,557,991 +inf%
3.96
US$6,166,840 		1,557,991 +inf% 3.96 US$6,166,840
2016-02-16 2016-02-11 B Purchase Flynn James E Large shareholder
1,224,136 +inf%
3.96
US$4,845,375 		1,224,136 +inf% 3.96 US$4,845,375
2016-01-22 2016-01-20 B Purchase Flynn James E Large shareholder
346,417 +5.5%
4.09
US$1,418,404 		346,417 +5.5% 4.09 US$1,418,404
2015-11-13 2015-11-11 S Sale Freund John Gordon Non-Executive Director
909 -0.2%
6.68
US$6,074 		909 -0.2% 6.68 US$6,074
2015-07-15 2015-07-15 PlS Planned sale Barrett Ronald W

Chief Executive Officer

Executive Director
12,500 -5.8%
7.20
US$90,000 		12,500 -5.8% 7.20 US$90,000
2015-05-12 2015-05-11 B Purchase WIERENGA WENDALL Non-Executive Director
5,000 +20.8%
5.63
US$28,169 		5,000 +20.8% 5.63 US$28,169
2014-12-12 2014-12-10 S Sale RIEFLIN WILLIAM JL Non-Executive Director
2,500 -10.3%
8.49
US$21,225 		2,500 -10.3% 8.49 US$21,225
2014-12-12 2014-12-10 S Sale RIEFLIN WILLIAM JL Non-Executive Director
5,592 -18.8%
8.49
US$47,476 		5,592 -18.8% 8.49 US$47,476
2014-12-12 2014-12-10 S Sale RIEFLIN WILLIAM JL Non-Executive Director
2,918 -8.9%
8.49
US$24,774 		2,918 -8.9% 8.49 US$24,774
2014-12-10 2014-12-08 S Sale Barrett Ronald W

Chief Executive Officer

Executive Director
3,000 -1.8%
8.40
US$25,200 		3,000 -1.8% 8.40 US$25,200
2014-12-10 2014-12-08 S Sale Barrett Ronald W

Chief Executive Officer

Executive Director
2,000 -1.2%
8.35
US$16,700 		2,000 -1.2% 8.35 US$16,700
2014-12-10 2014-12-08 S Sale Barrett Ronald W

Chief Executive Officer

Executive Director
1,015 -0.6%
8.32
US$8,445 		1,015 -0.6% 8.32 US$8,445
2014-12-10 2014-12-08 S Sale BATES GREGORY T

SVP, Regulatory Affairs & QA

Officer
9,581 -31.6%
8.35
US$80,001 		9,581 -31.6% 8.35 US$80,001
2014-12-10 2014-12-08 S Sale BATES GREGORY T

SVP, Regulatory Affairs & QA

Officer
4,585 -18.1%
8.35
US$38,285 		4,585 -18.1% 8.35 US$38,285
2014-12-10 2014-12-08 S Sale Barrett Ronald W

Chief Executive Officer

Executive Director
1,000 -0.6%
8.30
US$8,303 		1,000 -0.6% 8.30 US$8,303
2014-12-08 2014-12-05 S Sale Bosko Gianna M

SVP, CLO and Secretary

Officer
20,000 -20.6%
8.40
US$168,000 		20,000 -20.6% 8.40 US$168,000
2014-12-08 2014-12-05 S Sale Bosko Gianna M

SVP, CLO and Secretary

Officer
21,348 -21.7%
8.45
US$180,418 		21,348 -21.7% 8.45 US$180,418
2014-12-08 2014-12-04 S Sale Bosko Gianna M

SVP, CLO and Secretary

Officer
7,399 -8.8%
8.50
US$62,897 		7,399 -8.8% 8.50 US$62,897
2014-12-08 2014-12-04 S Sale Bosko Gianna M

SVP, CLO and Secretary

Officer
11,253 -12.7%
8.50
US$95,658 		11,253 -12.7% 8.50 US$95,658
2014-09-10 2014-09-09 S Sale BATES GREGORY T

SVP, Regulatory Affairs & QA

Officer
5,612 -21.3%
5.26
US$29,519 		5,612 -21.3% 5.26 US$29,519
2014-06-04 2014-06-03 B Purchase Freund John Gordon Non-Executive Director
12,500 +123.4%
3.93
US$49,164 		12,500 +123.4% 3.93 US$49,164
2014-05-27 2014-05-27 B Purchase FRIEDMAN CATHY Non-Executive Director
2,600 +inf%
3.92
US$10,179 		2,600 +inf% 3.92 US$10,179
2014-05-27 2014-05-27 B Purchase WIERENGA WENDALL Non-Executive Director
10,000 +71.4%
3.99
US$39,900 		10,000 +71.4% 3.99 US$39,900
2014-05-27 2014-05-27 B Purchase FENTON DENNIS M Non-Executive Director
3,000 +30.0%
4.02
US$12,046 		3,000 +30.0% 4.02 US$12,046
2014-05-28 2014-05-23 B Purchase Barrett Ronald W

Chief Executive Officer

Executive Director
2,600 +1.5%
3.75
US$9,745 		2,600 +1.5% 3.75 US$9,745
2014-05-27 2014-05-23 B Purchase Freund John Gordon Non-Executive Director
9,500 +81.2%
3.72
US$35,354 		9,500 +81.2% 3.72 US$35,354
2014-05-27 2014-05-23 B Purchase MARIO ERNEST Non-Executive Director
30,000 +55.8%
3.73
US$111,978 		30,000 +55.8% 3.73 US$111,978
2014-05-27 2014-05-22 B Purchase Freund John Gordon Non-Executive Director
5,500 +88.7%
3.75
US$20,623 		5,500 +88.7% 3.75 US$20,623
2014-05-16 2014-05-15 PlS Planned sale BERNS PAUL L Non-Executive Director
2,500 -33.3%
3.66
US$9,150 		2,500 -33.3% 3.66 US$9,150
2013-06-17 2013-06-14 S Sale BATES GREGORY T

SVP, Regulatory Affairs & QA

Officer
7,500 -31.2%
5.35
US$40,125 		7,500 -31.2% 5.35 US$40,125
2013-05-23 2013-05-22 B Purchase MARIO ERNEST Non-Executive Director
20,000 +200.0%
5.49
US$109,800 		20,000 +200.0% 5.49 US$109,800
2012-08-09 2012-08-09 B Purchase MARIO ERNEST Non-Executive Director
10,000 +inf%
8.50
US$84,983 		10,000 +inf% 8.50 US$84,983
2011-12-16 2011-12-16 B Purchase RIEFLIN WILLIAM JL Non-Executive Director
10,000 +3.7%
3.86
US$38,580 		10,000 +3.7% 3.86 US$38,580
2011-11-22 2011-11-21 B Purchase RIEFLIN WILLIAM JL Non-Executive Director
10,000 +3.8%
4.44
US$44,413 		10,000 +3.8% 4.44 US$44,413
2011-11-09 2011-11-07 B Purchase RIEFLIN WILLIAM JL Non-Executive Director
5,000 +2.0%
5.49
US$27,452 		5,000 +2.0% 5.49 US$27,452
2010-11-12 2010-11-12 B Purchase FENTON DENNIS M Non-Executive Director
300 +30.0%
7.86
US$2,358 		300 +30.0% 7.86 US$2,358
2010-11-12 2010-11-12 B Purchase FENTON DENNIS M Non-Executive Director
35 +3.6%
7.87
US$275 		35 +3.6% 7.87 US$275
2010-11-12 2010-11-12 B Purchase FENTON DENNIS M Non-Executive Director
100 +11.6%
7.92
US$792 		100 +11.6% 7.92 US$792
2010-11-12 2010-11-12 B Purchase FENTON DENNIS M Non-Executive Director
100 +13.1%
7.93
US$793 		100 +13.1% 7.93 US$793
2010-11-12 2010-11-12 B Purchase FENTON DENNIS M Non-Executive Director
765 +inf%
7.94
US$6,071 		765 +inf% 7.94 US$6,071
2010-02-04 2010-02-01 PlS Planned sale Cundy Kenneth C

SVP, Preclinical Development

Officer
100 -0.7%
18.47
US$1,847 		100 -0.7% 18.47 US$1,847
2010-02-04 2010-02-01 PlS Planned sale Cundy Kenneth C

SVP, Preclinical Development

Officer
100 -0.7%
18.43
US$1,843 		100 -0.7% 18.43 US$1,843
2010-02-04 2010-02-01 PlS Planned sale Cundy Kenneth C

SVP, Preclinical Development

Officer
100 -0.7%
18.58
US$1,858 		100 -0.7% 18.58 US$1,858
2010-02-04 2010-02-01 PlS Planned sale Cundy Kenneth C

SVP, Preclinical Development

Officer
100 -0.7%
18.61
US$1,861 		100 -0.7% 18.61 US$1,861
2010-02-04 2010-02-01 PlS Planned sale Cundy Kenneth C

SVP, Preclinical Development

Officer
100 -0.7%
18.52
US$1,852 		100 -0.7% 18.52 US$1,852
2010-02-04 2010-02-01 PlS Planned sale Cundy Kenneth C

SVP, Preclinical Development

Officer
100 -0.6%
18.50
US$1,850 		100 -0.6% 18.50 US$1,850
2010-02-04 2010-02-01 PlS Planned sale Cundy Kenneth C

SVP, Preclinical Development

Officer
100 -0.6%
18.46
US$1,846 		100 -0.6% 18.46 US$1,846
2010-02-04 2010-02-01 PlS Planned sale Cundy Kenneth C

SVP, Preclinical Development

Officer
100 -0.6%
18.39
US$1,839 		100 -0.6% 18.39 US$1,839
2010-02-04 2010-02-01 PlS Planned sale Cundy Kenneth C

SVP, Preclinical Development

Officer
100 -0.6%
18.32
US$1,832 		100 -0.6% 18.32 US$1,832
2010-02-04 2010-02-01 PlS Planned sale Cundy Kenneth C

SVP, Preclinical Development

Officer
100 -0.6%
18.30
US$1,830 		100 -0.6% 18.30 US$1,830
2010-02-04 2010-02-01 PlS Planned sale Cundy Kenneth C

SVP, Preclinical Development

Officer
200 -1.2%
18.36
US$3,672 		200 -1.2% 18.36 US$3,672
2010-02-04 2010-02-01 PlS Planned sale Cundy Kenneth C

SVP, Preclinical Development

Officer
200 -1.2%
18.49
US$3,698 		200 -1.2% 18.49 US$3,698
2010-02-04 2010-02-01 PlS Planned sale Cundy Kenneth C

SVP, Preclinical Development

Officer
100 -0.6%
18.57
US$1,857 		100 -0.6% 18.57 US$1,857
2010-02-04 2010-02-01 PlS Planned sale Cundy Kenneth C

SVP, Preclinical Development

Officer
200 -1.2%
18.60
US$3,720 		200 -1.2% 18.60 US$3,720
2010-02-04 2010-02-01 PlS Planned sale Cundy Kenneth C

SVP, Preclinical Development

Officer
30 -0.2%
18.79
US$564 		30 -0.2% 18.79 US$564
2010-02-04 2010-02-01 PlS Planned sale Cundy Kenneth C

SVP, Preclinical Development

Officer
2 -0.0%
18.80
US$38 		2 -0.0% 18.80 US$38
2010-02-04 2010-02-01 PlS Planned sale Cundy Kenneth C

SVP, Preclinical Development

Officer
68 -0.4%
18.81
US$1,279 		68 -0.4% 18.81 US$1,279
2010-02-04 2010-02-01 PlS Planned sale Cundy Kenneth C

SVP, Preclinical Development

Officer
100 -0.6%
18.68
US$1,868 		100 -0.6% 18.68 US$1,868
2010-02-04 2010-02-01 PlS Planned sale Cundy Kenneth C

SVP, Preclinical Development

Officer
100 -0.6%
18.72
US$1,872 		100 -0.6% 18.72 US$1,872
2010-01-06 2010-01-04 PlS Planned sale Cundy Kenneth C

SVP, Preclinical Development

Officer
100 -0.7%
19.20
US$1,920 		100 -0.7% 19.20 US$1,920
2010-01-06 2010-01-04 PlS Planned sale Cundy Kenneth C

SVP, Preclinical Development

Officer
100 -0.7%
19.17
US$1,917 		100 -0.7% 19.17 US$1,917
2010-01-06 2010-01-04 PlS Planned sale Cundy Kenneth C

SVP, Preclinical Development

Officer
100 -0.7%
19.52
US$1,952 		100 -0.7% 19.52 US$1,952
2010-01-06 2010-01-04 PlS Planned sale Cundy Kenneth C

SVP, Preclinical Development

Officer
100 -0.7%
19.36
US$1,936 		100 -0.7% 19.36 US$1,936
2010-01-06 2010-01-04 PlS Planned sale Cundy Kenneth C

SVP, Preclinical Development

Officer
32 -0.2%
19.26
US$616 		32 -0.2% 19.26 US$616
2010-01-06 2010-01-04 PlS Planned sale Cundy Kenneth C

SVP, Preclinical Development

Officer
268 -1.8%
19.25
US$5,159 		268 -1.8% 19.25 US$5,159
2010-01-06 2010-01-04 PlS Planned sale Cundy Kenneth C

SVP, Preclinical Development

Officer
200 -1.4%
19.28
US$3,856 		200 -1.4% 19.28 US$3,856
2010-01-06 2010-01-04 PlS Planned sale Cundy Kenneth C

SVP, Preclinical Development

Officer
100 -0.7%
19.23
US$1,923 		100 -0.7% 19.23 US$1,923
2010-01-06 2010-01-04 PlS Planned sale Cundy Kenneth C

SVP, Preclinical Development

Officer
200 -1.3%
19.22
US$3,844 		200 -1.3% 19.22 US$3,844
2010-01-06 2010-01-04 PlS Planned sale Cundy Kenneth C

SVP, Preclinical Development

Officer
100 -0.7%
19.27
US$1,927 		100 -0.7% 19.27 US$1,927
Explore more

More insider trading research around XenoPort Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Pharmaceuticals companies with insider activity
Insider trading in North America